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Valacyclovir was administered to 28 immunocompromised children (ages 5–12 years) to
obtain preliminary pharmacokinetic and safety information. Patients were randomized to
valacyclovir regimens of 250 mg (9.4–13.3 mg/kg) or 500 mg (13.9–27.0 mg/kg) twice daily or
500 mg (13.2–21.7 mg/kg) 3 times a day. Acyclovir pharmacokinetics were evaluated at steady
state. Valacyclovir was rapidly absorbed and converted to acyclovir. Mean (SD) acyclovir
peak concentrations from 250 mg and 500 mg valacyclovir were and4.11 1.41 5.19
mg/mL, respectively. Corresponding single dose area-under-curve values were 11.96 2.14
and . By using historical data for intravenous acyclovir as refer-6.60 14.49 4.69h mg/mL
ence, the overall estimate of acyclovir bioavailability from valacyclovir was 48%, 2- to 4-fold
greater than for oral acyclovir. In general, adverse events were not attributable to valacyclovir
and were consistent with disease-related expectations and concomitant therapies. Dosage
options for using valacyclovir in children are discussed.
Herpesvirus infections are very common but can be severe
and even life threatening in immunocompromised persons [1].
Oral acyclovir is safe and effective for the management of her-
pes simplex virus (HSV) [2, 3] and varicella-zoster virus (VZV)
infections [4–7] and has been used for prophylaxis against cy-
tomegalovirus infection in organ transplant recipients [8, 9].
However, its low oral bioavailability (∼10%–20%) coupled with
its rapid elimination necessitates frequent dosing (up to 5 times/
day) [3, 10, 11]. Intravenous infusion of acyclovir provides in-
creased acyclovir exposure and allows the treatment of more
severe or the complicated infections seen in immunocomprom-
ised persons [10].
The pharmacokinetics of acyclovir was studied in children
with normal renal function for age and who were at risk of
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HSV or VZV infections [12, 13]. After intravenous adminis-
tration, pharmacokinetic characteristics in those aged 1 year
appeared similar to those of adults. The average plasma elim-
ination half-life was 2.5 h, and there was little or no evidence
of drug accumulation on repeat dosing. Acyclovir clearance
among children aged 2–12 years averaged (SD) 360 120
mL/min/1.73m2 and did not differ appreciably across the age
range; this value is comparable with that reported for adults
( mL/min/1.73m2) [12]. In children aged 6 months to327 80
7 years given oral acyclovir suspension, the average acyclovir
bioavailability following a weight-normalized dose of 25 mg/
kg was about 11% [13]. This estimate is similar to that for adults
receiving high oral doses of 800 mg [12].
Valacyclovir is an oral prodrug of acyclovir that can produce
systemic acyclovir exposures similar to those observed after
intravenous acyclovir infusion in both immunocompetent and
immunocompromised subjects [14–17]. Estimates of average
acyclovir bioavailability from oral valacyclovir in different
adult populations are 54%–70%. Current clinical experience
with valacyclovir in children is extremely limited [18–20], but
clinicians have wide interest in its use in children because of its
potential to achieve higher systemic acyclovir concentrations
than are possible with oral acyclovir, the possibility of less fre-
quent dosing regimens for HSV treatment and prophylaxis, and
because the need for intravenous acyclovir administration could
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be minimized, potentially allowing the convalescent child to be
treated at home.
The purpose of this pilot study was to provide preliminary
steady-state pharmacokinetic and safety information for acy-
clovir after oral valacyclovir administration to immunocom-
promised children. The 250- and 500-mg doses of valacyclovir
administered 2 or 3 times a day in this study correspond to
doses (milligram/square meter/day) similar to those from ap-
proved regimens for prophylaxis or treatment of HSV infection
in immunocompromised adults (500 or 1000 mg twice/day, re-
spectively) or for VZV treatment in immunocompetent adults
(1000 mg 3 times/day).
Materials and Methods
Patient selection. Children aged 5–12 years with a body surface
area (BSA) of 0.6–1.25 m2 were eligible for study participation if
they were hospitalized, immunocompromised as a result of disease
or its treatment (e.g., cancer chemotherapy, human immunodefi-
ciency virus infection [HIV], or organ transplant recipient), con-
sidered at risk for HSV or VZV infection, required antiviral ther-
apy, and were able to take oral medication. Patients were excluded
if they had creatinine clearance !80 mL/min/1.73m2 BSA, acute or
unstable heart failure, impaired liver function (aspartate trans-
aminase or alanine transaminase 15 times the upper limit of nor-
mal), malabsorption syndrome (vomiting, mucositis, or other gas-
trointestinal dysfunction that could affect drug absorption), a
history of hypersensitivity to acyclovir or valacyclovir, or partici-
pated in a clinical trial with a new chemical entity within 2 weeks
of screening. Other reasons for exclusion were concurrent therapy
with probenecid, theophylline, mycophenolate mofetil, or systemic
acyclovir.
Study design and procedures. This was an open-label, random-
ized, parallel group, multicenter study conducted at six sites in
France, Switzerland, and Belgium. At prestudy screening, the pa-
tients’ characteristics were recorded, a brief medical history was
obtained, and other evaluations for study eligibility were per-
formed, including physical examination, 12-lead electrocardio-
gram, hematologic assessment, clinical chemistries, and urinalysis.
When feasible, creatinine clearance was estimated from a 24-h urine
collection; otherwise it was calculated from body height and serum
creatinine according to the method of Schwartz et al. [21]. A blood
sample was also obtained to monitor for any thrombotic microan-
giopathy (TMA)-like symptoms. TMA was suspected in a child
with microangiopathic hemolytic anemia (schistocytosis and ane-
mia) and thrombocytopenia and either renal abnormality (serum
creatinine assessment and urinalysis) or neurologic abnormality
and fever.
Patients were randomized (day 0) by use of a computer-generated
randomization schedule into 1 of 4 groups (nominally 6 patients
per group) according to BSA. Those with BSA of 0.6–0.89 m2 were
randomized to either 250 mg (group 1) or 500 mg (group 2) of
valacyclovir every 12 h; those with BSA of 0.9–1.25 m2 were ran-
domized to either 500 mg every 12 h (group 3) or 500 mg of
valacyclovir every 8 h (group 4). Valacyclovir was administered for
a minimum of 5 doses. Pharmacokinetic sampling was done after
the first dose on day 3 (i.e., after 5 doses for subjects on twice daily
regimens or after 7 doses for subjects on the 3 times/day regimen).
Valacyclovir was administered as 250-mg tablets (supplied by
GlaxoSmithKline, UK) swallowed with either 5–10 mL of syrup
BP (66.7% sucrose in water), immediately followed by an additional
100 mL of syrup BP, or swallowed with a comparable volume of
water or juice. Valtrex tablets were taken with syrup BP, if possible,
to aid in swallowing. Each dose was consumed within a 5-min
interval. Due to its interference with the valacyclovir assay, patients
were not permitted to consume any artificial sweetener containing
aspartame from days 0 to 4. Patients refrained from consuming
caffeine-containing foods or beverages from midnight on day 2
until 12 h after administration of the morning dose on day 3. Unless
considered to interfere with adequate nutrition and hydration for
the individual, patients fasted from midnight on day 2 until 2 h
after the morning dose on day 3 and did not drink any fluids for
a 2-h period after the day-3 dose.
Sample collection and analysis. In association with the morning
dose on day 3, 2-mL blood samples were taken via a cannula
inserted into a forearm vein or via an already existing cannula or
central venous catheter just before drug administration and then
at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 h after dosing. For all samples,
a small volume of blood was aspirated and discarded prior to
collection for drug concentration assays. The plasma was separated
and stored frozen at 40C prior to analysis of valacyclovir and
acyclovir concentrations by previously validated methods. Acyclo-
vir was analyzed by scintillation proximity RIA [22] and valacy-
clovir was assayed by high-performance liquid chromatography
with UV detection [15]. Samples were diluted into the validated
calibration ranges of 1.4–90 ng/mL (6.2–400 nM) for acyclovir and
80–3243 ng/mL (0.25–9.99 mM) for valacyclovir. Accuracy (% bias)
and precision (% coefficient of variation) were calculated by using
interpolated concentrations of quality control samples at 3 con-
centration levels. Accuracy and precision were less than or equal
to 6.8% and 15%, respectively, for acyclovir assays and were less
than or equal to 4.6% and 12%, respectively, for valacyclovir
assays. The lower limits of quantitation were 14 ng/mL for acy-
clovir and 80 ng/mL for valacyclovir.
Pharmacokinetic analyses. Plasma concentration time data
were analyzed by standard noncompartmental pharmacokinetic
methods with use of WinNonlin Pro software (v3.0; Pharsight).
The observed peak concentration (Cmax) and the time to reach peak
concentration (Tmax) were taken directly from the observed con-
centration time profiles. The elimination rate constant (l) was ob-
tained from regression of data in the terminal log linear portion
of the concentration time profile for each subject and the plasma
elimination half-life (T1/2) was calculated as T1/2 p ln2/l. The area
under the plasma concentration time curve (AUC0–t) over a steady-
state dosing interval of duration t (where or 12 h) was cal-tp 8
culated by using log linear trapezoidal approximation. For acy-
clovir, apparent oral clearance (CL/F) was calculated as dose/
AUC0– and apparent volume of distribution (Vz/F) was
determined as (CL/F)/l. Since acyclovir constitutes 69.4% of va-
lacyclovir, in estimation of acyclovir CL/F, the value for “dose”
was taken to be equal to 0.694 times the valacyclovir dose, reflecting
the maximum amount of acyclovir systemically available upon
complete absorption and deesterification of the prodrug to
acyclovir.
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Table 1. Summary characteristics at screening for children included in pharmacokinetic analyses.
Group,
valacyclovir regimen Diagnosis
Age, years
median (range)
Boys/
girls
Weight, kg
median (range)
Height, cm
median (range)
BSA, m2
median (range)
CLcr, mL/min
median (range)
Group 1 (n p 8),
250 mg (2/day)
ALL, LT, 3 each;
RMS, HIV, 1 each 6.5 (5–9) 4/4 21.7 (18.8–26.5) 119.5 (101–125) 0.81 (0.66–0.88) 114 (101–139)
Group 2 (n p 5)
500 mg (2/day)
ALL, 3; AnL, H-X,
1 each 5.0 (5–8) 4/1 22.0 (18.5–25.0) 114 (110–121) 0.77 (0.70–0.84) 130 (120–155)
Group 3 (n p 5),
500 mg (2/day)
ALL, 3; BMT, HIV,
1 each 11 (11–11) 4/1 30.0 (26.0–36.0) 144 (128–153) 1.03 (0.90–1.16) 118 (107–127)
Group 4 (n p 6),
500 mg (3/day)
ALL, 3; AML, ES,
WAS, 1 each 11 (8–12) 4/2 30.5 (23.0–38.0) 139 (122–145) 1.05 (0.82–1.12) 121 (101–189)
NOTE. ALL, acute lymphoblastic leukemia; AML, acute megaloblastic leukemia; AnL, anaplastic lymphoma; BMT, bone marrow transplant; BSA,
body surface area; CLcr, estimated creatinine clearance; ES, Ewing’s sarcoma; HIV, human immunodeficiency virus infection; H-X, histiocytosis-X; LT,
liver transplant; RMS, rhabdomyosarcoma; WAS, Wiskott-Aldrich syndrome.
Statistical analyses. Statistical analysis to obtain information
on dose proportionality and to assess pharmacokinetic differences
related to age or body size was conducted by comparing results
between selected cohorts. Group 1 (250 mg twice a day; BSA
0.6–0.89 m2) and group 2 (500 mg twice a day; BSA 0.6–0.89 m2)
were compared for dose proportionality and groups 2 and 3 (500
mg twice a day; BSA 0.9–1.25 m2) were compared for potential
effects of age and/or body size on pharmacokinetics. For the dose
proportionality comparison between groups 1 and 2, values for
Cmax, trough acyclovir concentration (Cmin), and AUC0– from the
250-mg dose were first normalized to a 500-mg dose. Groups 3 and
4 were also evaluated for pharmacokinetic differences between 500
mg at 2 and 3 times a day dosing. Log transformed Cmax, AUC0–,
and T1/2 were analyzed separately by use of analysis of variance.
Comparative estimates between groups were based on the ratio of
the geometric least square means (LSmean) with the associated 90%
confidence interval (90% CI) (Statistical Analysis Systems, SAS
Institute).
Safety assessments. In addition to laboratory evaluations at
prestudy screening, blood samples were taken on day 4 for serum
creatinine analysis for TMA and 14 days after study completion
for final assessment of hematology, plasma biochemistry, TMA-
related analysis, and urinalysis. Adverse events were monitored
from the start of dosing until poststudy follow-up. All adverse
events were categorized by severity (mild, moderate, or severe),
seriousness, and the physician’s considered relationship to study
drug. Safety data and laboratory evaluations were assessed without
inferential analysis.
Results
Patients. In total, 28 immunocompromised children aged
5–12 years were enrolled in the study and received at least 1
dose of study drug. However, only 24 subjects had evaluable
pharmacokinetic data for analysis (see below). Table 1 sum-
marizes the characteristics at enrollment of these 24 subjects.
Most children (13 of 24) were immunocompromised due to
leukemia, 3 were liver transplant recipients, 1 was a bone mar-
row transplant (BMT) recipient, 2 were infected with HIV, and
1 each were diagnosed with rhabdomyosarcoma, Ewing’s sar-
coma, anaplastic lymphoma, histiocytosis-X, and Wiskott-Al-
drich syndrome. The pharmacokinetic population consisted of
16 boys and 8 girls and all presented with normal renal function
as characterized by estimated creatinine clearance.
Two subjects withdrew prematurely from the study and 2
were excluded from the pharmacokinetic analysis. Two subjects
received drug only on the first day of dosing. One of these
subjects, an 8-year-old BMT recipient, was withdrawn from the
study due to vomiting thought to be associated with increasing
intestinal graft-versus-host disease. Oral medication was no
longer considered advisable and she was treated with intrave-
nous acyclovir. The other child, a 5-year-old liver transplant
patient, withdrew after 2 doses because of difficulty swallowing
study drug tablets. Two other children received the minimum
number of doses according to the protocol prior to pharma-
cokinetic sampling, but either no samples were collected (a 6-
year-old girl with acute lymphoblastic leukemia in group 2) or
data were excluded from analysis (an 11-year-old girl BMT
patient in group 4). The latter subject vomited after the morning
dose on day 3 and shortly thereafter received a second dose.
Data for this subject were excluded from the pharmacokinetic
analysis because of the uncertainty of ingested dose amount
just prior to and during pharmacokinetic sampling.
Valacyclovir and acyclovir pharmacokinetics. Valacyclovir
was rapidly absorbed and converted to acyclovir. Plasma con-
centrations of the unchanged prodrug were below the lower
limit of quantitation (0.08 mg/mL) for all subjects within 4 h
after dosing. Measurable valacyclovir concentrations were not
available for estimation of elimination rate, half-life or AUC0–.
Nine subjects (4 of 8 in group 1, 1 of 5 in each of groups 2
and 3, and 3 of 6 in group 4) had no quantifiable valacyclovir
concentrations at any time point. Plasma valacyclovir concen-
trations were !0.5 mg/mL at all sampling times. Mean (SD)
peak valacyclovir concentrations were ,0.09 0.12 0.20
, , and mg/mL for groups 1–4, re-0.17 0.26 0.17 0.13 0.19
spectively. The corresponding postdose sampling times for sub-
jects with measurable concentrations were 1.00, 1.75, 1.13, and
1.50 h, respectively.
Table 2 lists pharmacokinetic parameter estimates for acy-
clovir after multiple dose valacyclovir administration. The
mean (SD) values for Cmax were , ,4.11 1.41 5.17 2.13
, and mg/mL for groups 1–4, respec-5.12 2.12 5.27 2.08
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Table 2. Summary pharmacokinetic parameters for acyclovir from valacyclovir administration.
Parameter
Body surface area 0.6–0.9 m2 Body surface area 0.9–1.25 m2
Group 1 (n p 8),
250 mg 2/day
Group 2 (n p 5),
500 mg 2/day
Group 3 (n p 5),
500 mg 2/day
Group 4 (n p 6),
500 mg 3/day
Mean  SD Median (range) Mean  SD Median (range) Mean  SD Median (range) Mean  SD Median (range)
Cmax (mg/mL) 4.11  1.41 3.95 (1.98–6.73) 5.17  2.13 6.23 (2.19–7.13) 5.12  2.12 4.67 (2.82–7.55) 5.27  2.08 5.89 (2.43–7.21)
Tmax (h) 2.19  0.75 2.00 (1.00–3.00) 2.57  0.76 3.00 (1.50–3.28) 1.41  0.39 1.50 (1.00–1.98) 2.62  0.48 2.90 (2.00–3.00)
AUC0–t
(h  mg/mL) 12.14  6.60 10.14 (7.82–28.11) 15.35  4.62 15.84 (9.03–21.70) 13.26  4.56 14.00 (8.29–18.31) 14.80  5.47 14.37 (7.28–21.30)
T1/2 (h) 2.11  0.35 2.06 (1.72–2.71) 2.00  0.37 1.95 (1.66–2.54) 2.51  0.28 2.48 (2.14–2.79) 2.34  0.40 2.23 (1.96–2.99)
CL/F, mL/min 275  82 285 (103–370) 409  141 365 (267–640) 485  179 413 (316–698) 448  195 408 (271–794)
mL/min/m2 349  92 382 (154–456) 536  174 508 (346–821) 478  193 401 (315–775) 430  149 387 (299–709)
mL/min/kg 12.5  3.3 13.5 (5.5–16.4) 19.0  5.7 18.8 (12.1–27.8) 16.1  6.7 13.8 (9.9–26.8) 14.6  5.1 12.8 (11.4–24.8)
Vz/F, L 48.7  13.7 48.6 (24.1–69.5) 69.7  21.6 61.5 (50.6–93.7) 105.1  37.5 99.2 (58.4–150.0) 87.8  33.2 75.5 (61.3–147.8)
L/m2 61.8  14.3 60.4 (36.0–85.8) 90.7  23.5 87.9 (65.7–117.8) 103.5  40.8 96.3 (62.1–166.6) 85.0  25.1 76.1 (62.6–131.9)
L/kg 2.21  0.55 2.12 (1.28–3.08) 3.21  0.70 3.25 (2.30–3.99) 3.49  1.43 3.31 (2.21–5.77) 2.90  0.89 2.70 (2.16–4.62)
NOTE. AUC0–t, area under concentration-time curve over a steady state dosing interval of duration t; CL/F, apparent oral clearance; Cmax, peak concentration;
T1/2, elimination half-life; Tmax, time to peak concentration; Vz/F, apparent volume of distribution.
tively. Estimates for AUC0–t over one steady-state dosing in-
terval, theoretically equal to AUC from time zero to infinity
(i.e., AUC0–) after a single dose, were ,12.14 6.60 15.35
, , and for groups 1–4,4.62 13.26 4.56 14.80 5.47h mg/mL
respectively. One subject in group 1, a 7-year-old liver transplant
patient, had an unusually high AUC0–t ( ) rel-28.11h mg/mL
ative to other children receiving the 250-mg dose and, in fact,
had the highest AUC estimated for all children in the study.
Exclusion of this patient’s estimate resulted in an AUC0– for
group 1 of .9.86 1.51 h mg/mL
The plasma T1/2 was similar among cohorts, with mean values
of 2.06–2.48 h. These half-life estimates indicate that attainment
of steady state was assured by the time of pharmacokinetic
sampling on day 3 of dosing. Apparent oral clearance and
volume of distribution appear lower for group 1 relative to the
other cohorts, possibly reflecting the higher bioavailability for
the lower 250-mg dose. Normalization of apparent clearance
and volume of distribution to either body weight or BSA re-
sulted in estimates generally showing somewhat smaller vari-
ability (coefficient of variation) compared with the nonnor-
malized parameters. With the exception of the 1 patient with
high AUC0–, acyclovir pharmacokinetics in the liver transplant
patients (all 3 in group 1) were similar to those observed for
the other subjects who received the 250-mg twice a day regimen.
Table 3 shows the statistical evaluations of dose proportion-
ality and of the effect of age and/or body size on acyclovir
pharmacokinetics. For the dose proportionality assessment
(group 1 vs. group 2), dose-normalized comparisons of acyclo-
vir pharmacokinetic parameters indicated that Cmax and
AUC0– from the 250-mg dose were greater than would be
expected for dose-independent kinetics. The LSmean ratio (90%
CI) for Cmax was 1.64 (1.08–2.51), and for AUC0–Pp .057
1.51 (1.04–2.19), . The high ratios probably reflect aPp .073
decrease in acyclovir bioavailability with the higher valacyclovir
dose. There were no differences detected in values for Cmin or
T1/2 between these cohorts.
In assessment of the effects of age and/or size on pharma-
cokinetics (group 2 vs. group 3), no differences were found in
Cmax, Cmin, or AUC0–. T1/2 appeared somewhat shorter in the
younger/smaller children (LSmean ratio, 0.79 [90% CI, 0.67–0.94],
). Acyclovir pharmacokinetics was very similar betweenPp .03
groups 3 and 4, with the anticipated exception of lower trough
concentrations from valacyclovir administration twice a day as
compared with 3 times a day (LSmean ratio, 0.28 [90% CI,
0.14–0.57], ).Pp .006
Safety. In all, 67 adverse events were reported for 18 of
the 28 subjects enrolled. The most common were pain (27 re-
ports in 13 patients; e.g., headache, abdominal, or gastrointes-
tinal pain), fever (9 observations in 7 patients), and vomiting
and diarrhea (4 patients each). One child reported dizziness.
Adverse events were generally considered mild or moderate in
intensity and consistent with disease and treatment expectations
for the children in the study. Most children with adverse events
(11/18) had acute lymphoblastic leukemia and 10 of the 13 with
this diagnosis received chemotherapy during study participa-
tion. No child discontinued therapy because of an adverse
event.
Only 1 adverse event, a mild increase in haptoglobin in a
patient with acute lymphoblastic leukemia observed 5 days after
administration of the last of 5 500-mg valacyclovir doses, was
thought possibly to be related to valacyclovir; the event was
not considered serious. One acute lymphoblastic leukemia pa-
tient died of septic shock after participating in the study for 6
days. The only other serious adverse event was a case of gas-
trointestinal viral infection with mild and intermittent viral di-
arrhea beginning 2 days after the onset of dosing in a 5-year-
old boy in group 2 with histiocytosis-X. The event was
considered unrelated to study drug and resolved within 2 days
without dosage adjustment. There were no other serious ad-
verse event reports. One case of severe mucositis in a 5-year
old with lymphoblastic leukemia that started 5 days after the
end of valacyclovir administration was treated and resolved
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Table 3. Summary of statistical analysis (ANOVA) of acyclovir
pharmacokinetic parameters after valacyclovir administration to
children.
Parameter,
group comparison
(test vs. reference)
Geometric LSmean
Test reference
ratio (90% CI
for ratio)
ANOVA
P valueTest Reference
AUC0– (h  mg/mL)
Group 1 vs. group 2 22.28a 14.76 1.51 (1.04–2.19) .073
Group 2 vs. group 3 14.76 12.59 1.17 (0.77–1.78) .52
Group 3 vs. group 4 12.59 13.88 0.91 (0.61–1.35) .68
Cmax (mg/mL)
Group 1 vs. group 2 7.79a 4.74 1.64 (1.08–2.51) .057
Group 2 vs. group 3 4.74 4.76 0.99 (0.62–1.59) .98
Group 3 vs. group 4 4.76 4.87 0.98 (0.62–1.53) .93
Cmin (mg/mL)
Group 1 vs. group 2 0.14a 0.12 1.17 (0.60–2.28) .69
Group 2 vs. group 3 0.12 0.10 1.19 (0.57–2.50) .68
Group 3 vs. group 4 0.10 0.36 0.28 (0.14–0.57) .006
T1/2 (h)
Group 1 vs. group 2 2.08 1.98 1.05 (0.90–1.23) .59
Group 2 vs. group 3 1.98 2.50 0.79 (0.67–0.94) .030
Group 3 vs. group 4 2.50 2.31 1.08 (0.92–1.28) .42
NOTE. AUC0–, area under concentration-time curve; Cmax, peak concen-
tration; Cmin, trough concentration; CI, confidence interval; T1/2, elimination half-
life.
a AUC0–, Cmax, and Cmin for 250-mg dose (group 1) were normalized to 500
mg for dose proportionality comparison.
with intravenous acyclovir. All other adverse events were mild
or moderate in intensity.
Serum creatinine measurements on study day 4 and at follow-
up showed no changes relative to prestudy screen. Median se-
rum creatinine values from all subjects at baseline, day 4, and
at follow-up were 49, 50, and 49 mM (or 0.6 mg/dL at each
assessment), respectively. As for this overall result, there were
no apparent changes in serum creatinine within dose groups.
Similarly, there were no other apparent changes in hematology
or clinical chemistry that were considered clinically significant
or related to valacyclovir administration. Monitoring for de-
velopment of TMA-like events revealed no signs or symptoms
suggestive of this diagnosis.
Discussion
In this pilot study, we obtained preliminary pharmacokinetic,
safety, and tolerability information for valacyclovir after mul-
tiple dose oral administration to immunocompromised children
aged 5–12 years. The 250- and 500-mg valacyclovir regimens
appeared to be well tolerated, and adverse events were consis-
tent with disease-related expectations and concomitant medi-
cations received by the immunocompromised children. Serum
creatinine levels remained unchanged relative to baseline in the
study as a whole and in individual dose groups. No signs or
symptoms that could relate to TMA were observed.
At the 500-mg twice a day valacyclovir dosage, no apparent
differences in acyclovir pharmacokinetics were observed be-
tween cohorts of different age or body size (group 2 vs. group
3, table 3). However, such differences may not have been de-
tectable in this pilot investigation due to the small number of
subjects per cohort and enrollment of subjects 5 years old.
Differences in dose-normalized acyclovir pharmacokinetic
parameters from patients of comparable age and size who re-
ceived 250 compared with 500 mg of valacyclovir doses (group
1 vs. group 2, table 3) suggest a decrease in acyclovir bioa-
vailability with increasing dose. In a previous study, the average
acyclovir systemic clearance from intravenous acyclovir ad-
ministration to immunocompromised children aged 2–12 years
was mL/min/1.73m2 [12]. In the current study, the360 120
average CL/F estimate (normalized to comparable units) from
all subjects was mL/min/1.73m2, suggesting that acy-753 270
clovir bioavailability averaged about 48% overall. However, the
mean (SD) CL/F estimate was mL/min/1.73m2 for603 159
the children who received 250 mg of valacyclovir and 827
mL/min/1.73m2 for those receiving 500 mg of valacyclovir.286
Compared with the acyclovir clearance from intravenous dos-
ing, these CL/F values indicate that acyclovir bioavailability
was about 60% from the 250-mg dose (mean, 11.6 mg/kg of
valacyclovir; range 9.4–13.3) and about 44% from the 500-mg
dose (mean, 19.0 mg/kg of valacyclovir; range, 13.2–27.0).
These estimates are consistent with observations of dose-de-
pendent acyclovir bioavailability and similar in range to esti-
mates of 42%–64% from valacyclovir administration to adults
[14, 15]. In addition, the overall estimate of 48% is similar to
the absolute bioavailability estimate of 45% in studies [18] of
immunocompromised children given intravenous acyclovir and
oral valacyclovir.
As with previous findings in adults [14, 15], valacyclovir was
rapidly absorbed and converted to acyclovir in children. In
comparison with adults with normal renal function who re-
ceived doses of 250 and 500 mg of valacyclovir [15], mean
(SD) acyclovir peak concentrations were higher in the chil-
dren (250 mg, vs. mg/mL; 500 mg,2.20 0.39 4.11 1.41
vs. mg/mL for groups 2–4 combined).3.37 0.97 5.19 1.96
Similarly, acyclovir AUC values after valacyclovir dosing in
children were greater than for adults (250 mg, vs.5.68 0.82
; 500 mg, vs.9.86 1.51 h mg/mL 11.13 1.75 14.49
for groups 2–4 combined). Given the apparent4.69 h mg/mL
similarity in bioavailability, the higher acyclovir exposures seen
in children at these fixed dose levels of valacyclovir probably
reflect the higher doses in children relative to body size. On a
body weight basis, the 250- and 500-mg doses administered to
the children in this study ranged from 9.4 to 27.0 mg/kg. In
contrast, comparable doses in adult men of normal weight
(70–75 kg) would correspond to valacyclovir doses of 750–2000
mg.
Figure 1 shows Cmax and AUC values based on body weight
for children and adults. Children and adults experience similar
decreases in acyclovir bioavailability with increasing valacyclo-
vir dose. The renal excretion of acyclovir suggests that the lower
Cmax and AUC values for children at a given milligram per
kilogram (mg/kg) dose reflect the higher renal clearance in chil-
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Figure 1. Valacyclovir administration to immunocompromised children. A, Acyclovir peak concentration (Cmax). B, Acyclovir area under
concentration time curve (AUC0–) over a steady-state dosing interval. Linear regression results for children given valacyclovir doses based on
mg/kg body weight. For comparison (mg/kg basis), historical results ( ) from healthy adults given fixed doses of 100, 250, 500, 750,mean SD
1000, 1500, and 2000 mg of valacyclovir are displayed (data from [15]).
dren compared with adults. Given comparable bioavailability,
comparison of the regression lines for AUC in figure 1B sug-
gests that acyclovir renal clearance was about 1.5 times greater
for children 5–12 years old in this trial than for adults. This is
consistent with normal age-related changes in renal function
[23].
In this study we observed slightly reduced variability in pa-
rameter estimates for clearance and volume of distribution
when these were normalized to either body weight or BSA (table
2). Although the variabilities were similar whether normalized
by weight or BSA, dosing on the basis of body weight is simple
and convenient.
Intravenous acyclovir regimens of 10 or 20 mg/kg every 8 h
or of 250 or 500 mg/m2 every 8 h are used for the treatment
or prophylaxis of herpesvirus infections in adults and children.
Assuming an acyclovir systemic clearance of mL/360 120
min/1.73m2 in children after intravenous acyclovir [12], intra-
venous administration of 250 mg/m2 of acyclovir every 8 h
should provide a mean (SD) daily AUC (AUC0–24) of 60
in children with normal renal function. Figure 220h mg/mL
displays the range of daily acyclovir AUC values resulting from
this intravenous regimen along with estimates for individual
subjects from 3 times a day oral valacyclovir administration
data generated in the current study.
Modest extension of the regression line suggests that a daily
acyclovir AUC value comparable to that from 250 mg/m2 in-
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Figure 2. Mean daily acyclovir AUC from oral valacyclovir administration (mg/kg) every 8 h () compared with estimate frommean SD
intravenous acyclovir 250 mg/m2 every 8 h in immunocompromised children. Best-fit line (solid line) and its 95% confidence interval (dashed line)
from regression of daily AUC on mg/kg dose are displayed. Intravenous acyclovir AUC was estimated by assuming an acyclovir systemic clearance
of mL/min/1.73m2 [12].360 120
Table 4. Valacyclovir dosage regimens corresponding to intravenous
and oral acyclovir regimens for consideration in children with normal
renal function.
Proposed valacyclovir
weight-based regimen
by body weight rangea
Valacyclovir
dosage regimen
(mg 3/day)
Current standard
acyclovir regimen
30 mg/kg, 3/day 250 mg/m2 or 10 mg/kg
3 times/day iv
4–12 kg 250b
13–21 kg 500
22–29 kg 750
30 kg 1000
20 mg/kg, 3/day 20 mg/kg 4 or 5 times/day
orally
6–19 kg 250b
20–31 kg 500
32 kg 750
NOTE. Dosage reduction is required for children with renal impairment.
Only low-dose intravenous (iv) acyclovir regimens are included due to limitations
in data from the current study.
a Children with body weights of !18.5 or 138 kg were not within weight range
of children 5–12 years old evaluated in this study.
b 250–mg valacyclovir tablets are not available in some countries.
travenous acyclovir 3 times a day would be obtained with a
valacyclovir regimen of about 30 mg/kg 3 times a day. Allowing
for variability in the data generated in our study, the 95% CI
for the regression line indicates that a regimen of 22–25 mg/kg
3 times a day may be sufficient to provide comparable average
systemic exposures. Peak acyclovir concentrations from intra-
venous dosing in pediatric patients average and10.3 4.0
mg/mL from 250 and 500 mg/m2 dosing every 8 h,20.7 5.0
respectively [12]. By comparison, the projected acyclovir Cmax
from 30 mg/kg of valacyclovir is about 7–8 mg/mL (figure 1A).
This reduced peak concentration should provide an added mar-
gin of safety relative to intravenous acyclovir.
Acyclovir suspension or tablets (800 mg/dose) administered
4 or 5 times a day is commonly used to treat or prevent HSV
or VZV infections in immunocompromised children. These re-
sult in typical acyclovir peak plasma concentrations of about
1.5–2 mg/mL [12, 16, 24]. Assuming a 20% oral acyclovir bi-
oavailability, 20 mg/kg of oral acyclovir 5 times a day should
provide a daily AUC of about in children with40h mg/mL
normal renal function. With its higher bioavailability, a com-
parable daily AUC would be expected from about 20 mg/kg
of valacyclovir 3 times a day. The expected acyclovir Cmax from
this valacyclovir regimen (∼5–6 mg/mL) would be greater than
from oral acyclovir and similar to that for adults receiving 1000
mg of valacyclovir 3 times a day for the treatment of herpes
zoster (figure 1A).
Potential valacyclovir dosage regimens for use in immuno-
compromised children with normal renal function are proposed
in table 4. These regimens account for the fact that acyclovir
constitutes about 69% of valacyclovir labeled strength. No va-
lacyclovir dosage regimen can be derived from available data
to correspond to high-dose intravenous acyclovir (500 mg/m2
or 20 mg/kg every 8 h). The regimens include body weights
outside of the range evaluated in the current study but are
included for completeness based on available tablet strengths
and mg/kg dose considerations. Of importance, as with acy-
clovir, added caution is needed and doses must be reduced for
patients with renal impairment.
As an alternative to the valacyclovir dosing considerations
with fixed tablet strengths, physicians may wish to consider use
of the extemporaneous suspension preparation described by
Fish et al. [25]. Pharmacokinetic results from comparison of
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this formulation with the marketed 500-mg tablet in 8 pediatric
patients suggest similar, but slightly reduced, acyclovir bioa-
vailability [20]. This approach would allow for refined mg/kg
dosing and permit such dosage for young children who cannot
swallow tablets. Crushed valacyclovir tablets in standard syrup
BP usually are not palatable to children. Also, valacyclovir is
unstable in aqueous solution or suspension. Thus, it may be
necessary to administer valacyclovir via nasogastric tube in
certain situations.
When considered clinically appropriate, oral valacyclovir
could be substituted for intravenous acyclovir, avoiding the
need for hospitalization. Oral valacyclovir may also be used in
place of oral acyclovir, allowing less frequent administration
and possibly providing improved efficacy because of higher
drug levels and potentially increased compliance. The results
from this study provide preliminary guidance for valacyclovir
dosing to immunocompromised children and should facilitate
the design of clinical trials to investigate the efficacy and safety
of valacyclovir in pediatric populations.
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